Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ladarixin - Dompe Farmaceutici

Drug Profile

Ladarixin - Dompe Farmaceutici

Alternative Names: DF-2156A; DF-2156Y; Meraxin

Latest Information Update: 15 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dompe Farmaceutici
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Bullous pemphigoid; Malignant melanoma; Spinal cord injuries

Most Recent Events

  • 15 May 2019 Dompé Farmaceutici completes phase II trial for Type 1 diabetes mellitus in Germany, Belgium and Italy (NCT02814838)
  • 24 Jun 2018 Biomarkers information updated
  • 30 Jan 2018 Phase-II development for Type-I diabetes mellitus (Newly diagnosed) is ongoing in Italy (PO) (EudraCT2014-003968-20) (NCT02814838)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top